AI
Tuesday, April 25, 2017 11:13:29 AM
3. EXOSOME Joint Venture – IPO Valuation HUGH
THE EXOSOME BILLION DOLLARS WORLDWIDE RAPID DEPLOY STRATEGY, we can only hope
Exosome blood test "first in" preventive early detection and post-treatment monitoring sector,
plus
the Exosome blood test "locating body part and stage of cancer" initial determination" and
"during-treatment monitoring" second sector.
I propose that for this disruptive technology in the overall cancer treatment cycle, we need to put a top notch management team in charge, teamed with a brand-name-recognized distribution partner.
Hence, Ronin should formulate a spin-off for the kit manufacturing and marketing operation, placed off-shore for cost and tax advantagse (the parent can always "loan those excess profits") and get a fair and instant valuation with an IPO.
Such IPO does then reflect on the PPHM share price by reference, not to mention the (for Peregrine) enormous publicity in a new a stock offer, and thus potentially accelerating the Exosome makrkets and even the step-child Bavi partnering.
Further, the Exosome Corporate structure should be set
60% Peregrine (input the IP, patents and initial process knowhow), with 9% distributed to PPHM shareholders by formula, retaining 51% stock control
15% Ronin, holding and appointing a majority in the Ex Corp board , and selecting the Ex Corp management, for the three year start-up period, and buying into the IPO
15% public offering
10% reserved for buy-in by the distribution partner, based on marketing performance milestones.
Now for contraversy, the 9% distributed as a special dividend to PPHM shareholders, that is excluding management held options and off-shore accounts, so here we just target retail long term holders and institutions, at distribution formula:
first 30,000 PPHM shares == 300 Ex Corp shares
next 70,000 == 200
all next 100,000s and fractions == 100 and fractional pro rata
PPHM shares at 300 million outstanding == 300,000 Ex Corp shares to be distributed (9% of total)
hence total common is 3.33 million Ex Corp shares (rounded, assumed for this breakdown only)
third year earnings, at $357million, or eps of $107, early trendsetter market, and excluding start-up expenses for the evolving Exosome markets, our Ex Corp share price then $1000 minimum, which means an IPO at astronomical, eh? -- here is high growth potential, way beyond the "initial trendsetter market fragment" that the $357million minimum is factored from above. AND WE HAVE A REAL NEW MANAGEMENT AND MARKETING TEAM. Hence IPO is feasable
Next, base lines of the current oncology market and diagnostics/testing parameters.
THE EXOSOME BILLION DOLLARS WORLDWIDE RAPID DEPLOY STRATEGY, we can only hope
Exosome blood test "first in" preventive early detection and post-treatment monitoring sector,
plus
the Exosome blood test "locating body part and stage of cancer" initial determination" and
"during-treatment monitoring" second sector.
I propose that for this disruptive technology in the overall cancer treatment cycle, we need to put a top notch management team in charge, teamed with a brand-name-recognized distribution partner.
Hence, Ronin should formulate a spin-off for the kit manufacturing and marketing operation, placed off-shore for cost and tax advantagse (the parent can always "loan those excess profits") and get a fair and instant valuation with an IPO.
Such IPO does then reflect on the PPHM share price by reference, not to mention the (for Peregrine) enormous publicity in a new a stock offer, and thus potentially accelerating the Exosome makrkets and even the step-child Bavi partnering.
Further, the Exosome Corporate structure should be set
60% Peregrine (input the IP, patents and initial process knowhow), with 9% distributed to PPHM shareholders by formula, retaining 51% stock control
15% Ronin, holding and appointing a majority in the Ex Corp board , and selecting the Ex Corp management, for the three year start-up period, and buying into the IPO
15% public offering
10% reserved for buy-in by the distribution partner, based on marketing performance milestones.
Now for contraversy, the 9% distributed as a special dividend to PPHM shareholders, that is excluding management held options and off-shore accounts, so here we just target retail long term holders and institutions, at distribution formula:
first 30,000 PPHM shares == 300 Ex Corp shares
next 70,000 == 200
all next 100,000s and fractions == 100 and fractional pro rata
PPHM shares at 300 million outstanding == 300,000 Ex Corp shares to be distributed (9% of total)
hence total common is 3.33 million Ex Corp shares (rounded, assumed for this breakdown only)
third year earnings, at $357million, or eps of $107, early trendsetter market, and excluding start-up expenses for the evolving Exosome markets, our Ex Corp share price then $1000 minimum, which means an IPO at astronomical, eh? -- here is high growth potential, way beyond the "initial trendsetter market fragment" that the $357million minimum is factored from above. AND WE HAVE A REAL NEW MANAGEMENT AND MARKETING TEAM. Hence IPO is feasable
Next, base lines of the current oncology market and diagnostics/testing parameters.
